By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Regen BioPharma  

4700 Spring Street
Suite 304
La Mesa  California  91942  U.S.A.
Phone: 619-702-1404 Fax: 619-330-2328


Company News
Regen BioPharma Develops BORIS Gene Silencing Based Treatment For Unresectable Liver Cancer 8/31/2015 6:51:34 AM
Regen BioPharma BORIS Gene Silencing Technology Successfully Utilized By Independent Researchers To Kill Breast Cancer And Colon Cancer Stem Cells 8/24/2015 7:47:34 AM
Regen BioPharma Progresses In FDA Responses To dCellVax Clinical Trial Questions 8/10/2015 9:45:29 AM
Regen BioPharma Successfully Completes In Life Portion Of Experiments Requested By FDA For HemaXellerate Pre-Clinical Study 7/21/2015 7:55:27 AM
Regen BioPharma Presents Preclinical Proof-Of-Concept Of Diffronc Effectiveness At The International Society for Stem Cell Research Annual Meeting 7/14/2015 6:52:59 AM
Regen BioPharma Reports Successful Dosing Of HemaXellerate In FDA-Requested GLP Animal Study 7/9/2015 9:52:38 AM
Regen BioPharma Announces Presentation At The International Society for Stem Cell Research 13th Annual Meeting In Stockholm, Sweden 6/16/2015 10:49:47 AM
Regen BioPharma Receives Notice Of Allowance For U.S. Patent For Screening Of Small Molecules Against Its Nuclear Receptor Target 6/12/2015 11:14:51 AM
Cancer Clinical Trials Expert Dr. Santosh Kesari To Assist Regen BioPharma In Addressing FDA Questions Regarding Planned dCellVax Immunotherapy Clinical Trial For Breast Cancer 6/10/2015 7:26:18 AM
Regen BioPharma Recruits Retinoid Experts Dr. Hinrich Gronemeyer, Dr. William S. Blaner, and Dr. Louise Purton To Serve On Scientific Advisory Board 6/5/2015 10:17:07 AM